Status: Not yet recruiting
SAD Study of CGB3002 in Healthy Participants
This is a randomized, double-blind, placebo-controlled phase I clinical study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of single ascending IV doses of CGB3002 in healthy participants. CGB3002 is being developed to treat Alzheimer's Disease.
Participants needed: 46
Trial details
Phase: Phase 1Age: 18-55Biological sex: AllType: InterventionalSponsor: ChainGen Biopharma LtdUpdated: Jun 22, 2026Locations: 1
Eligibility criteria
Must have signed written informed consent before any study-related activities ar... [+3]
A known history of clinically significant drug allergy or atopic allergic diseas... [+15]